Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 8/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153308 | 0.91 | METAP2 (0.48) | DGAT1KCNH2SOAT1 | |
| SCHEMBL4148421 | 0.90 | DGAT1 (0.57) | NPBWR1DGAT1KCNH2SOAT1EGLN1 | |
| SCHEMBL4138826 | 0.89 | NPBWR1 (0.48) | NPBWR1DGAT1KCNH2SOAT1CBFB | |
| SCHEMBL4181974 | 0.87 | NPBWR1 (0.57) | NPBWR1DGAT1KCNH2SOAT1CBFB | |
| SCHEMBL4151516 | 0.87 | NPBWR1 (0.46) | NPBWR1DGAT1KCNH2SOAT1CBFB | |
| SCHEMBL15252715 | 0.86 | DGAT1 (0.53) | NPBWR1DGAT1KCNH2SOAT1CBFB | |
| SCHEMBL4153761 | 0.85 | MMP2 (0.57) | DGAT1KCNH2SOAT1EGLN1 | |
| SCHEMBL4140019 | 0.84 | EGLN1 (0.48) | NPBWR1DGAT1KCNH2SOAT1CBFB | |
| SCHEMBL13741444 | 0.84 | KDM4E (0.52) | DGAT1KCNH2SOAT1ATR | |
| SCHEMBL4149320 | 0.84 | NPBWR1 (0.52) | NPBWR1DGAT1KCNH2SOAT1CBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | claimed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | claimed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-8436022-B2 | Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | TRPV1, TRPV3, TRPV5 | NPBWR1 840/4885DGAT1 2497/4885KCNH2 280/4885 |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TRPV1, TRPV3, TRPA1 | NPBWR1 383/4885DGAT1 3064/4885KCNH2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.